Filing Flows › Otter Tail (OTTR) › Guidance & outlook
Otter Tail (OTTR) guidance and outlook
Otter Tail (OTTR) narrowed its guidance on Nov 3, 2026: EPS +7% to +9% for long-term; Net income $100K for FY2026; EPS $3.89–$4.19 for FY2026; EPS $5.73–$6.03 for FY2026. Otter Tail's 10-Q filed Nov 4, 2026 makes 16 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EPS | long-term | +7% to +9% | reaffirmed |
| Net income | FY2026 | $100K | new |
| EPS | FY2026 | $3.89–$4.19 | reaffirmed |
| EPS | FY2026 | $5.73–$6.03 | reaffirmed |
| EPS | FY2026 | $1.84 | new |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- Our Plastics segment manufactures PVC pipe for use in, among other applications, municipal and rural water, wastewater, and water reclamation projects.
- Other Income (Expense), net increased $1.6 million primarily due to higher allowance for funds used during construction (AFUDC) in our Electric segment, reflecting continued investment in our Abercrombie and Solway solar projects.
- Operating and Maintenance expenses increased $9.0 million primarily due to higher labor costs, driven by a lower level of labor capitalization resulting from the timing of construction project activity, increased vegetative management expenses, plant outage-related costs, and an increase in insurance costs.
- Other Income (Expense), net increased $2.2 million primarily due to an increase in AFUDC driven by capital investments in our Abercrombie and Solway solar projects.
- Our wind repowering projects were completed in late 2025 and early 2026.
- Other Income (Expense), net increased $4.0 million primarily due to higher AFUDC in our Electric segment, reflecting continued investments in our Abercrombie and Solway solar projects.
- In addition, the Company's effective tax rate decreased in 2026 compared with 2025 due to higher PTCs generated by its wind generation facilities following the completion of repowering projects at certain facilities in late 2025 and early 2026.
- Other Income (Expense), net increased $4.7 million primarily due to an increase in AFUDC driven by capital investments in our Abercrombie and Solway solar projects.
- The following provides a summary of general rates, rate rider, and other regulatory filings that have or are expected to have a material impact on our operating results, financial position, or cash flows.
- If this part of the request is granted, we anticipate the amounts collected would be deferred and recognized over the remaining estimated useful life of the plant, which extends until 2041.
- We currently anticipate the case will be finalized in April 2027, and that final rates will go into effect in the second half of 2027.
- We currently anticipate the MPUC will hold deliberations and render a decision on the IRP in 2027.
Otter Tail's latest quarter
Otter Tail, Q3 2026: revenue $317M (-3% year over year), operating margin 21.7%, net earnings $59.5M, operating cash flow $125M. The chart follows the revenue to costs, profit and cash.
Questions
Did Otter Tail raise or lower its guidance?
Otter Tail (OTTR) narrowed its guidance on Nov 3, 2026: EPS +7% to +9% for long-term; Net income $100K for FY2026; EPS $3.89–$4.19 for FY2026; EPS $5.73–$6.03 for FY2026.
What does Otter Tail expect?
Our Plastics segment manufactures PVC pipe for use in, among other applications, municipal and rural water, wastewater, and water reclamation projects. Other Income (Expense), net increased $1.6 million primarily due to higher allowance for funds used during construction (AFUDC) in our Electric segment, reflecting continued investment in our Abercrombie and Solway solar projects. Operating and Maintenance expenses increased $9.0 million primarily due to higher labor costs, driven by a lower level of labor capitalization resulting from the timing of construction project activity, increased vege
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.